Vernakalant
- Generic Name
- Vernakalant
- Brand Names
- Brinavess
- Drug Type
- Small Molecule
- Chemical Formula
- C20H31NO4
- CAS Number
- 794466-70-9
- Unique Ingredient Identifier
- 9G468C8B13
- Background
Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA.
- Indication
Indicated for the rapid conversion of recent onset of atrial fibrillation to sinus rhythm in adults for non-surgery patients that lasts for less than 7 days of duration and post-cardiac surgery patients with atrial fibrillation lasting less than 3 days of duration.
- Associated Conditions
- Atrial Fibrillation
Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients
- Conditions
- Atrial FibrillationPost-cardiac Surgery
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 50
- Registration Number
- NCT04748991
RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 350
- Registration Number
- NCT04485195
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦Vancouver General Hospital, Vancouver, British Columbia, Canada
🇨🇦Montreal Heart Institute, Montreal, Quebec, Canada
Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents
- Conditions
- Paroxysmal Atrial Fibrillation
- Interventions
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- David Filgueiras-Rama
- Target Recruit Count
- 50
- Registration Number
- NCT03005366
- Locations
- 🇪🇸
Hospital Clínico Universitario San Carlos, Madrid, Madrid/Madrid, Spain
Vernakalant Versus Flecainide: Atrial Contractility
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2012-07-20
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 70
- Registration Number
- NCT01646281
- Locations
- 🇳🇱
Maastricht University Hospital, Maastricht, Netherlands
A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Advanz Pharma
- Registration Number
- NCT01627106
Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 101
- Registration Number
- NCT01447862
- Locations
- 🇦🇹
Medical University of Vienna, Department of Emergency Medicine, Vienna, Austria
Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Correvio International Sarl
- Target Recruit Count
- 2015
- Registration Number
- NCT01370629
- Locations
- 🇩🇪
St-Vincenz Krankenhaus, Paderborn, Germany
🇪🇸Hospital Universitario Severo Ochoa, Madrid, Spain
🇸🇪Skanes Universistetssjukhus, Malmo, Sweden
A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: Placebo to vernakalent hydrochloride
- First Posted Date
- 2010-08-03
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Advanz Pharma
- Target Recruit Count
- 123
- Registration Number
- NCT01174160
A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- Advanz Pharma
- Target Recruit Count
- 217
- Registration Number
- NCT00989001
A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2009-12-15
- Lead Sponsor
- Advanz Pharma
- Target Recruit Count
- 254
- Registration Number
- NCT00668759
- Locations
- 🇦🇺
Royal Perth Hospital Emergency Research, Perth, Western Australia, Australia
🇩🇰Gentofte Amtssygehus Kardiologisk afdeling, Hellerup, Denmark
🇩🇰Herlev Amtssygehus, Kardiologisk, Herlev, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.